Butorphanol tartrate

This product and its main metabolites stimulate K-opioid peptide receptors, and have both stimulatory and antagonistic effects on U-receptors. It mainly interacts with these receptors in the central nervous system (CNS) to indirectly exert its pharmacological effects, including analgesic effects. In addition to analgesic effects, the effects on the CNS include reducing spontaneous breathing of the respiratory system, coughing, exciting the vomiting center, miosis, sedation and other pharmacological effects. Its effects may be achieved through non-CNS mechanisms. For example, it changes the resistance and capacitance of the heart and blood vessels (nerves), bronchial motor tension, gastrointestinal secretion, motor muscle activity and bladder sphincter activity.

Butorphanol tartrate, its chemical name is: L-(-)-17-cyclobutylmethyl-3,14-dihydroxymorphan D-(-)-tartaric acid (1:1) salt.

This product is a colorless clear liquid

Used to treat various cancer pains and postoperative pains.

The intramuscular dose is 1-2 mg. If necessary, it can be repeated every 3-4 hours. There is no sufficient clinical data to recommend a single dose exceeding 4 mg. Or follow the doctor's advice.

Mainly drowsiness, dizziness, nausea and/or vomiting. Adverse reactions reported with an incidence of 1% or more may be considered to be related to butorphanol tartrate: Systemic: weakness, headache, feeling of heat. Cardiovascular system: vasodilation, palpitations. Digestive system: anorexia, constipation, dry mouth, stomach pain. Nervous system: anxiety, confusion, euphoria, floating, insomnia, nervousness, paresthesia, tremor. Respiratory system: bronchitis, cough, dyspnea, epistaxis, nasal congestion, nasal irritation, pharyngitis, rhinitis, sinusitis, sinus congestion, upper respiratory tract infection. Skin: sweating/clammy, itching. Special senses: blurred vision, earache, tinnitus, abnormal taste. Adverse reactions reported with an incidence of less than 1% may be considered to be related to butorphanol tartrate. Cardiovascular system: hypotension, syncope. Nervous system: abnormal dreams, anxiety, hallucinations, hostility, drug withdrawal symptoms. Skin: rash/wheal. Urinary system: urination disorder.

1. Patients who are allergic to this product or other ingredients in this product are prohibited from using this product. 2. Due to the antagonistic characteristics of opioids, this product is not suitable for patients who are dependent on narcotine. 3. Patients under 18 years old are prohibited from using this product.

Store away from light

24 months

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

• Founded in:

  1997-04-28

• Address:

  No. 38 Huanghe Road, Lianyungang Economic and Technological Development Zone

• Tax NO.:

  9132070070404786XB

• Registered Funds:

  6,379,002,274 yuan

• Website:

  Log in to view

• Email:

  Log in to view